Amphastar Pharmaceuticals Inc represents values of integrity, innovation, and commitment to patient care. As a leading pharmaceutical company, their corporate philosophy focuses on delivering high-quality and affordable medicines to improve health outcomes worldwide. Amphastar Pharmaceuticals Inc is dedicated to advancing medical knowledge and developing innovative therapies that address unmet medical needs. With their patient-centric approach, they strive to enhance access to life-saving medications, ensuring the well-being of individuals and communities. Their commitment to ethical practices and social responsibility is reflected in their extensive range of high-value generic and proprietary products. Amphastar Pharmaceuticals Inc's dedication to excellence and patient welfare sets them apart in the pharmaceutical industry.

Amphastar Pharmaceuticals Inc is primarily present in the United States.

Amphastar Pharmaceuticals Inc has achieved significant milestones throughout its history. Some of these achievements include the successful development and commercialization of various generic and branded pharmaceutical products. The company has also received numerous regulatory approvals, expanded its product portfolio, and established strategic partnerships to enhance its market presence. With a strong focus on research and innovation, Amphastar Pharmaceuticals Inc continues to deliver high-quality and affordable medications to meet the needs of patients worldwide.

Amphastar Pharmaceuticals Inc, a leading pharmaceutical company, has a rich history and background in the healthcare industry. Established in 1996, Amphastar has grown to become a renowned provider of generic and biosimilar products worldwide. The company specializes in developing, manufacturing, and marketing a wide range of quality and affordable pharmaceuticals, including injectables, inhalation products, and intranasal sprays. Amphastar has achieved significant milestones over the years, including FDA approvals for various products and strategic partnerships with global pharmaceutical companies. Committed to enhancing patient care and achieving business excellence, Amphastar Pharmaceuticals Inc continues to shape the future of the healthcare industry through innovation and dedication.

The main competitors of Amphastar Pharmaceuticals Inc in the market include Teva Pharmaceutical Industries Ltd, Mylan N.V., and Novartis International AG.

Amphastar Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of Amphastar Pharmaceuticals Inc involves researching, developing, manufacturing, and marketing generic and specialty injectable and inhalation products. As a leading pharmaceutical company, Amphastar focuses on leveraging its extensive expertise in the development of complex generic and innovative specialty pharmaceuticals. By offering a diverse range of products to address critical medical needs, Amphastar aims to improve patient outcomes and enhance access to cost-effective medications. Furthermore, the company actively seeks partnerships and collaborations to expand its product portfolio and enhance its market presence. Amphastar Pharmaceuticals Inc remains committed to providing high-quality pharmaceuticals and driving healthcare advancements.

De Amphastar Pharmaceuticals K/W is 10,57.

De Amphastar Pharmaceuticals KUV is 2,61.

De AlleAktien Kwaliteitsscore voor Amphastar Pharmaceuticals is 8/10.

De verwachte Amphastar Pharmaceuticals omzet is 767,15 mln. USD.

De verwachte Amphastar Pharmaceuticals winst is 189,29 mln. USD.

Amphastar Pharmaceuticals Inc. is a publicly traded company based in California, USA, specializing in the development, manufacturing, and marketing of injectable and inhalable pharmaceutical products. It was founded in 1996 and has built a wide range of products used in various therapy areas such as anesthesia, cardiology, emergency medicine, oncology, endocrinology, and neurology. The main business of Amphastar is the manufacturing and sale of injectable generic drugs used in hospitals and healthcare facilities. Some of the notable products include Ampicillin and Cefazolin, antibiotics used for treating infections. The company also produces anesthesia medications such as Lidocaine, Ketamine, and Midazolam, as well as adrenaline used for life-threatening allergic reactions. Another area of business for Amphastar is injectable Heparin products used for preventing blood clots. These products are sold under the brand names Amphastar and Nanjing Pharmaceutical. Amphastar also produces and distributes Naloxone hydrochloride injections used for opioid overdoses, as well as Enoxaparin injections used for preventing blood clots in patients after surgeries. In addition to injectable products, Amphastar has a pipeline of inhalable products in development, which offer promising growth opportunities. These products are specifically intended for treating respiratory diseases such as COPD and asthma. They are sold under the brand names Primatene Mist and Epinephrine. The company also has a division in the contract manufacturing of pharmaceutical active ingredients and raw materials, including analysis and quality control. Amphastar's customers primarily consist of other pharmaceutical companies that are unable or unwilling to manufacture certain products themselves. Amphastar primarily operates in the USA but also exports a significant portion of its products to Europe, Asia, and other parts of the world. The company has distribution partners in many countries and collaborates closely with distributors and wholesalers to distribute its products. Amphastar's business model is based on a combination of manufacturing its own products, contract manufacturing, and expanding its product portfolio through the development of inhalable products. The company emphasizes high quality and strict regulatory standards to gain the trust of its customers and investors. Amphastar has obtained international GMP standards, FDA approval, and numerous other certifications to ensure the quality and safety of its products. In summary, Amphastar Pharmaceuticals Inc. is a leading provider of injectable pharmaceuticals, also involved in the development of inhalable products. The company has fueled its growth through a combination of its own products and contract manufacturing and aims to expand its product portfolio to increase market share in the USA and internationally.

Amphastar Pharmaceuticals keert een dividend van 0 USD uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Amphastar Pharmaceuticals of het bedrijf keert geen dividend uit.

De ISIN van Amphastar Pharmaceuticals is US03209R1032.

Het WKN van Amphastar Pharmaceuticals is A11664.

De ticker van Amphastar Pharmaceuticals is AMPH.

Binnen de laatste 12 maanden betaalde Amphastar Pharmaceuticals een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Amphastar Pharmaceuticals naar verwachting een dividend van 0 USD betalen.

De dividendrendement van Amphastar Pharmaceuticals is momenteel .

Amphastar Pharmaceuticals betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Amphastar Pharmaceuticals betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 USD verwacht. Dit komt overeen met een dividendrendement van 0 %.

Amphastar Pharmaceuticals wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Amphastar Pharmaceuticals van 8-7-2024 ter hoogte van 0 USD te ontvangen, moest je het aandeel voor de ex-datum op 8-7-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 8-7-2024.

In het jaar 2023 heeft Amphastar Pharmaceuticals 0 USD aan dividenden uitgekeerd.

De dividenden van Amphastar Pharmaceuticals worden in USD uitgekeerd.